Title: DYNAMIC ADJUSTMENT OF CAPTURE MANAGEMENT "SAFETY MARGIN"

Abstract: A cardiac stimulation system and associated capture management method are provided in which a safety factor, used in setting pacing pulse output energy, is automatically adjusted in response to the detection of indicators of a likely increase in pacing threshold. The method includes monitoring for increased pacing threshold indicators, which may also be associated with a compromised ability to perform a pacing threshold search. Such indicators may include, but are not limited to, the presence of arrhythmias, arrhythmia episode duration, pacing mode switches, refractory sensed events, and/or lead impedance changes. In response to the detection of a selected indicator of increased pacing threshold, the safety factor is automatically increased. After an increased pacing threshold indicator has not been detected for an interval of time, or if a pacing threshold search yields a result, the safety factor may be restored to a programmed value.
Published: with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.
DYNAMIC ADJUSTMENT OF CAPTURE MANAGEMENT "SAFETY MARGIN"

The present invention relates generally to the field of implantable cardiac stimulation devices and more particularly to an improved method for maintaining capture using an automatically adjusted safety factor for setting the pacing pulse energy.

Cardiac stimulation devices deliver appropriately timed electrical stimulation pulses to a patient’s heart to maintain a normal heart rhythm or improve synchronization of heart chambers. Patients having bradycardia, abnormalities of the heart’s natural conduction system, a propensity for arrhythmias, cardiac-related breathing disorders, hemodynamic insufficiency, or other cardiac-related conditions may benefit from cardiac pacing therapies delivered in one or more heart chambers.

In order to effectively pace the heart, an electrical impulse delivered to the heart must have sufficient energy to depolarize the myocardial cells. Depolarization of the myocardial cells in response to a pacing pulse is often referred to as “capture.” The cardiac electrogram signal evidencing capture, which is a P-wave in the atria or an R-wave in the ventricles, is generally referred to as an “evoked response.” The lowest pacing pulse energy that captures the heart may be referred to as the “pacing threshold” or “capture threshold”. The amplitude and duration of a pacing pulse are preferably set to produce a pacing pulse energy somewhat greater than the pacing threshold in order to ensure effective cardiac pacing.

However, in order to prolong the battery life of the implanted cardiac stimulation device, it is desirable to program the pacing pulse energy to be a minimum value that is considered safely above the pacing threshold. Therefore, the pacing pulse amplitude is commonly set equal to the measured pacing threshold multiplied by a “safety factor.” The resulting pacing pulse amplitude setting provides a safety margin that ensures capture despite small fluctuations that may occur in the pacing threshold.

Pacing threshold can change over time due to tissue encapsulation of the pacing electrodes, lead movement, changes in the patient’s clinical condition, changes in medical therapy, or other causes. A rise in pacing threshold can result in loss of capture and ineffective pacing therapy. Modern pacemakers typically include automatic pacing
threshold search algorithms that automatically adjust the pacing pulse energy to ensure pacing pulses remain above the pacing threshold, even if it varies over time. A pacing threshold search may deliver pacing pulses starting at an initially high pulse energy that is greater than the pacing threshold and then progressively decrease the pulse energy until capture is lost. The lowest pulse energy at which capture still occurs is determined as the pacing threshold.

Thus, capture management systems typically include monitoring for changes in the pacing threshold and monitoring for evidence of capture during pacing. Capture monitoring may be performed continuously or periodically and typically involves sensing an evoked P-wave or R-wave following pacing pulse delivery. If loss of capture is detected, a pacing threshold search is performed and a new pacing pulse energy is set based on the pacing threshold search result and the programmed safety factor.

Situations may arise, however, when the pacing threshold is likely to be increased yet a pacing threshold search either fails or yields unreliable results. For example, during and after an episode of atrial fibrillation (AF) or atrial flutter (AFL), the atrial pacing threshold is typically increased. A pacing threshold search may be unsuccessful due to unstable thresholds and/or sensing. In another example, if a lead has shifted or become dislodged, the pacing threshold is likely to be increased, but a pacing threshold search may be unsuccessful due to sensing characteristics that have also changed. The programmed safety factor used in setting the pacing pulse energy may not be sufficient to ensure capture during these situations.

The safety factor is typically a fixed value that is programmable by the clinician. A dynamically variable safety margin is proposed in U.S. Pat. No. 6,456,882, issued to Schloss. An automatic capture/threshold capability is generally disclosed wherein the safety margin is periodically increased or decreased according to the performance of the stimulation device, i.e., based upon the frequency of capture. In U.S. Pat. No. 6,456,879, issued to Weinberg, a method is generally disclosed for altering stimulation energy based on rheobase and/or chronaxie shift of a strength-duration curve. The strength-duration curve may be divided into two regions having differently sized safety margins.

There remains a need, however, for recognizing situations in which a rise in pacing threshold can be expected yet a pacing threshold search may not yield a result for appropriately adjusting the pacing pulse energy. In such situations, a larger safety factor is
needed for maintaining capture. It is desirable, therefore, to provide an improved cardiac stimulation system and associated capture management method that allows automatic adjustment of the safety factor as needed for maintaining capture during expected episodes of increased pacing threshold despite an inability to measure the pacing threshold.

The present invention addresses the above described need by providing a cardiac stimulation system and associated capture management method that includes an automatically adjustable safety factor responsive to the detection of indicators of a likely increase in pacing threshold. The method includes monitoring for conditions that are likely to be associated with an increased pacing threshold, which may also be associated with a compromised ability to perform a pacing threshold search. Such conditions may include, but are not limited to, the presence of arrhythmias, arrhythmia episode duration, pacing mode switches, refractory sensed events or events triggered by refractory sensed events such as a non-competitive atrial pacing period, and/or lead impedance changes. In response to the detection of any of these selected conditions as increased pacing threshold indicators, the safety factor is automatically increased to a predetermined setting. The safety factor may be applied to the pulse amplitude setting and/or the pulse width setting such that the overall pulse energy is increased.

The increased safety factor may be allowed to decay over time or restored to a programmed value when detected indicators triggering the increase in the safety factor have not been detected for a period of time. The safety factor may also be restored to its programmed value if a pacing threshold search is successful.

The system includes an implantable cardiac stimulation device and a set of associated electrodes coupled to the device for sensing cardiac electrical activity and for delivering stimulation pulses. The stimulation device includes sensing circuitry for sensing cardiac electrical activity from signals received from the electrodes; output circuitry for delivering cardiac stimulation pulses via the electrodes; and a control system for controlling the delivery of stimulation pulses such as the amplitude and duration of the pulses, the timing of pulse delivery, and the electrodes used to deliver the pulses. The control system may include dedicated integrated circuitry and/or a microprocessor and associated memory for storing control programs to be executed by the microprocessor. The control system initiates pacing threshold searches; monitors for increased pacing
threshold indicators; and manages the automatic adjustment of the safety factor in response to detecting or not detecting such indicators.

Thus the system and associated capture management method provided by the present invention allow the pacing pulse energy to be automatically increased according to an increased safety factor even when an increased pacing threshold is not measurable via a pacing threshold search. The methods of the present invention thereby ensure capture during situations that are associated with a rise in pacing threshold.

Figure 1 is an illustration of an exemplary cardiac stimulation device in which the present invention may be usefully practiced.

Figure 2 is a more detailed functional block diagram of the cardiac stimulation device illustrated in Figure 1.

Figure 3 is a flow chart providing an overview of a method for automatically adjusting the safety factor in response to detecting one or more indicators of a likely increase in pacing threshold in accordance with the present invention.

Figures 4A through 4C are plots of pulse amplitude changes over time which illustrate changes in the pulse amplitude that may be made in response to automatic adjustments to the safety factor in accordance with the method shown in Figure 3.

As indicated above, the present invention is directed toward an improved capture management method wherein the safety factor used in setting the output pulse energy is automatically adjusted in response to detecting conditions that are often associated with an increase in pacing threshold. The benefits provided by the present invention are applicable in both atrial and ventricular stimulation applications. Thus, the present invention may be realized in single, dual, or multichamber cardiac stimulation devices, capable of delivering a cardiac pacing therapy. The term “cardiac pacing therapy” is used herein to refer to any cardiac stimulation therapy that employs relatively low-energy stimulation pulses to depolarize the myocardial tissue to achieve a therapeutic effect. Cardiac pacing therapies may include but are not limited to, bradycardia pacing, cardiac resynchronization therapy, extra systolic stimulation therapies, overdrive pacing for treating or preventing arrhythmias or cardiac-related disordered breathing, and anti-tachycardia pacing therapies.
Figure 1 is an illustration of an exemplary cardiac stimulation device in which the present invention may be usefully practiced. Figure 1 illustrates the external configuration of a dual chamber cardiac stimulation device 26, which is provided with a hermetically sealed enclosure 18, typically fabricated of biocompatible metal such as titanium.

Mounted to the top of the enclosure 18 is a connector block assembly 12, which receives electrical connectors located on the proximal ends of leads 14 and 16. The combination of the leads 14 and 16 and the device 26 constitute an implantable cardiac stimulation system. A dual chamber cardiac stimulation device in which the present invention may be implemented is generally described in U.S. Pat. No. 5,507,782, issued to Kieval et al., which is hereby incorporated herein by reference.

Lead 16 is an atrial bipolar cardiac stimulation and sensing lead, carrying two electrodes 20 and 22. Electrodes 20 and 22 are used both to sense atrial depolarizations (P-waves) and to deliver atrial stimulation pulses. Atrial stimulation pulses may be delivered between electrodes 20 and 22 in a bipolar mode or between electrode 22 and the housing 18 of device 26 in a unipolar mode. Sensing of P-waves may occur between electrode 20 and electrode 22 in a bipolar sensing mode or between either of electrode 20 and 22 and the housing 18 of device 26 in a unipolar sensing mode.

Similarly, lead 14 represents a ventricular bipolar cardiac stimulation and sensing lead, carrying two electrodes 28 and 30. Electrodes 28 and 30 are used to sense and stimulate the ventricle. Sensing of ventricular depolarizations (R-waves) may be accomplished between electrodes 30 and 28 in a bipolar sensing mode or between either of electrodes 30 and 28 and the housing 18 of device 26 in a unipolar sensing mode. Bipolar ventricular stimulation may be accomplished between electrodes 30 and 28 or unipolar ventricular stimulation may be accomplished between electrode 30 and the conductive housing 18 of device 26.

Figure 2 is a more detailed functional block diagram of the cardiac stimulation device illustrated in Figure 1. The device circuit 300 is located within housing 18 of device 26 as illustrated in Figure 1. The bipolar leads 14 and 16 are illustrated schematically as coupled directly to the input/output circuit 320. However, in the actual implantable device they would, of course, be coupled by means of removable electrical connectors inserted in the connector block 12 illustrated in Figure 1.
Circuit 300 is divided generally into a microcomputer circuit 302 and an input/output circuit 320. An output amplifier circuit 340 includes a ventricular pulse generator circuit coupled to the ventricle of the heart 10 by means of electrodes 28 and 30 on lead 16 as well as an atrial pulse generator circuit coupled to the atrium of heart 10 by means of atrial electrodes 20 and 22, located on lead 14. Similarly, sense amplifier circuit 360 includes atrial and ventricular sense amplifiers coupled to the atrium and ventricle, respectively, by means of leads 14 and 16. The output circuit 340 and sense amplifier circuit 360 may contain pulse generators and sense amplifiers, respectively, corresponding to any of those presently employed in commercially available cardiac pacemakers.

Sensed atrial depolarizations (or P-waves) that are detected by the atrial sense amplifier, in response to an atrial signal received from atrial lead 14 exceeding an atrial P-wave sensing threshold, are communicated to the digital controller/timer circuit 330 on A-event line 352. Similarly, ventricular depolarizations (or R-waves) that are detected by the ventricular sense amplifier, in response to a ventricular signal received from ventricular lead 16 exceeding a ventricular R-wave sensing threshold, are communicated to the digital controller/timer circuit 330 on V-event line 354. In devices configured for the detection of arrhythmias, consecutively sensed R-waves and P-waves may be used for measuring various intervals, such as R-R intervals, P-P intervals, R-P intervals and P-R intervals, for use in detecting arrhythmias as will be described in greater detail below.

In the absence of a sensed event prior to the expiration of a related escape interval, a pacing pulse will be generated by input/output circuit 320. In order to trigger generation of a ventricular pacing pulse, digital controller/timer circuit 330 generates a trigger signal on V-trig line 342. Similarly, in order to trigger an atrial pacing pulse, digital controller/timer circuit 330 generates a trigger pulse on A-trig line 344.

Control of timing and other functions within the input/output circuit 320 is provided by digital controller/timer circuit 330, which includes a set of timers and associated logic. Digital controller/timer circuit 330 defines the basic pacing or escape intervals controlling the timing of atrial and ventricular pacing pulse delivery. An A-A escape interval is initiated on atrial sense (A-event) or atrial pace (A-pace) events. An atrial pacing pulse (A-pace) is triggered at the expiration of the A-A escape interval. A V-V escape interval is initiated on ventricular sense (V-event) or pace (V-pace) events, and a ventricular pulse pacing (V-pace) is triggered upon the expiration thereof. Digital
controller/timer circuit 330 also defines A-V intervals that commence following a sensed
A-event or a delivered A-pace, and upon the expiration thereof a ventricular pacing pulse
is triggered during atrial synchronized pacing modes. The specific values of the escape
intervals defined by timer circuit 330 are controlled by the microcomputer circuit 302 by
means of data and control bus 306 according to programmed parameter values and
operating modes.

A variety of mode switching features have been disclosed or implemented in
commercially available devices which respond to an excessively rapid atrial rhythm by
causing the pacing system to switch from an atrial synchronized pacing mode, such as
DDD/DDDR, to a non-synchronized mode such as VVI/VVIR or DDI/DDIR. Such mode
switching features are disclosed in U.S. Pat. No. 5,144,949, by Olson, U.S. Pat. No.
4,932,406 by Berkovits, all incorporated herein by reference in their entireties. In such
pacing systems, the primary purpose of the mode switch is to prevent the pacing system
from tracking a non-physiologic atrial rate. In accordance with the present invention, a
pacing mode switch may be used as an indicator of an increased pacing threshold. During
rapid atrial rhythms, the atrial substrate may be more difficult to capture. A pacing
threshold search may be difficult to perform due to altered sensing characteristics or a
fluctuating threshold or undesirable to perform during a potentially unstable rhythm.
Therefore, a pacing mode switch may be selected as indicator of increased atrial pacing
threshold, to which the device 26 responds by increasing the safety factor used in setting
the atrial pacing pulse energy.

Digital controller/timer circuit 330 also controls sensitivity settings of the sense
amplifiers 360 by means of sensitivity control 350 and defines time intervals for
controlling operation of the atrial and ventricular sense amplifiers in sense amplifier
circuit 360. A number of blanking and refractory intervals are typically defined, as is
well-known in the art, for controlling the sensing functions of sense amplifiers 360 and for
controlling how digital timer/controller circuit 330 responds to sensed events.

For example, an atrial refractory sensed event occurring during a post ventricular
atrial refractory period (PVARP) may trigger a non-competitive atrial pacing (NCAP)
period during which no atrial pacing pulse may occur. The non-competitive atrial pacing
period is intended to prevent triggering of atrial tachycardia by an atrial pacing pulse
delivered during the relative refractory period. In accordance with the present invention, the pacing pulse energy may be increased on the next pacing pulse delivered after a NCAP period. The pacing pulse energy may be increased by applying an increased safety factor to the pacing pulse amplitude setting and/or the pacing pulse width setting.

In the embodiment illustrated in Figure 2, device 26 is provided with a sensor 316, which may be a piezoelectric sensor intended to monitor patient activity, in order to allow provision of rate responsive pacing, such that the defined pacing rate (A-A escape interval or V-V escape interval) increases with increased levels of sensed activity. Sensor 316 generates electrical signals in response to sensed physical activity which are processed by activity/sensor circuit 322 and provided to digital controller/timer circuit 330. Similarly, the present invention may be practiced in conjunction with alternate types of physiological sensors such as oxygen sensors, pressure sensors, pH sensors and respiration sensors, all known for use in providing rate responsive pacing capabilities. The present invention may also be practiced in non-rate responsive pacemakers.

In alternative embodiments, a physiological sensor 316 and corresponding activity/sensor circuit 322 may alternatively be used for monitoring cardiac hemodynamic performance, myocardial contractile performance, a metabolic state or other physiological condition. Physiological sensors known for use in conjunction with implanted devices may include blood pressure sensors, oxygen saturation sensors, pH sensors, temperature sensors, blood flow sensors, acoustical sensors, accelerometers, impedance sensors and so forth. Signals from such sensors may be processed for determining a need for therapy delivery or therapy adjustment as a physiological condition or metabolic need changes. In accordance with the present invention, physiological signals that may indicate a change in the cardiac substrate may also be used as indicators of increased pacing threshold.

Data transmission to and from an external device, commonly known in the art as a "programmer," is accomplished by means of telemetry antenna 334 and an associated RF transmitter and receiver 332, which serves both to demodulate received downlink telemetry and to transmit uplink telemetry. For the purposes of the present invention, telemetry circuitry for communicating with an external device may correspond to any telemetry system known for use with implantable medical devices.

Threshold data from pacing threshold searches may be stored in the RAM 310 or the RAM/ROM unit 314 of microcomputer 302 for later telemetry out on command of an
external programmer. This data may be encoded in digital form and transmitted via RF transmitter 332 and antenna 334 to an external programmer for display and/or analysis in the form of atrial and ventricular strength-duration curves as described in U.S. Patent No. 5,601,615, issued to Markowitz et al., hereby incorporated herein by reference in its entirety. Data pertaining to detected increased pacing threshold indicators which trigger safety factor adjustments, in accordance with the present invention, may also be stored in RAM 310 for later telemetry out for diagnostic and therapy management purposes.

Crystal oscillator circuit 338 provides the basic timing clock for the input/output circuit 320, while battery 318 provides power. Power-on-reset circuit 336 responds to initial connection of the circuit to the battery for defining an initial operating condition and similarly, resets the operative state of the device in response to detection of a low battery condition. Reference mode circuit 326 generates stable voltage reference and currents for the analog circuits within the input/output circuit 320, while analog to digital converter (ADC) and multiplexer circuit 328 digitizes analog signals and voltage to provide real time telemetry of cardiac signals from sense amplifiers 360, for uplink transmission via RF transmitter and receiver circuit 332. Voltage reference and bias circuit 326, ADC and multiplexer 328, power-on-reset circuit 336 and crystal oscillator circuit 338 may correspond to any of those presently used in currently available implantable cardiac stimulation devices.

Microcomputer 302 controls the operational functions of digital controller/timer 330, specifying which timing intervals are employed, and controlling the duration of the various timing intervals, via data and control bus 306. Microcomputer 302 contains a microprocessor 304 and associated system clock 308 and on-processor RAM and ROM chips 310 and 312, respectively. In addition, microcomputer circuit 302 includes a separate RAM/ROM chip 314 to provide additional memory capacity. Microprocessor 304 is interrupt driven, operating in a reduced power consumption mode normally, and awakened in response to defined interrupt events, which may include the A-trig, V-trig, A-event and V-event signals.

Microprocessor 304 controls the scheduling of pacing threshold searches, either on a periodic or triggered basis, which are then executed by input/output circuit 320. For example, a pacing threshold search may be executed upon detection of loss of capture. For the purposes of the present invention, prior art circuitry and methods for performing
pacing threshold searches and capture detection may be implemented in conjunction with
the present invention. Examples of appropriate pacing threshold searching methods are
generally disclosed in the previously-incorporated U.S. Pat. No. 5,601,615 to Markowitz,
in U.S. Pat. No. 6,067,472 issued to Vonk et al., in U.S. Pat. No. 5,713,933 issued to
Condie et al., or U.S. Pat. No. 6,430,441 issued to Levine et al., all of which patents are
incorporated herein by reference in their entirety.

In accordance with the present invention, microprocessor 304 executes code stored
in associated memory 310 and 312 for detecting indicators of increased pacing threshold
and for automatically increasing the safety factor in response to an increased pacing
threshold indicator detection. A newly adjusted safety factor is then used by digital timer
and controller 330 to cause output circuit 340 to deliver pacing pulses at an output energy
set according to the most recent pacing threshold search result and the newly adjusted
safety factor.

Device 26 may further include lead impedance measuring circuitry 341 coupled to
leads 14 and 16 for monitoring changes in lead impedance. Implantable medical devices
capable of measuring and monitoring changes in lead impedance are generally disclosed in
U.S. Pat. No. 5,201,865 issued to Kuehn, U.S. Pat. No. 5,741,311 issued to McVenes et
al., and U.S. Pat. No. 6,317,633 issued to Jorgenson et al., all of which are incorporated
herein by reference in their entirety. A change in lead impedance may occur as the result
of shifting or dislodgement of a lead. Such a change may result in a change in pacing
threshold and/or may alter sensing characteristics making pacing threshold searches and
capture detection algorithms unreliable. As will be described below, a change in lead
impedance may therefore be selected as an indicator of a likely increase in pacing
threshold which may be used to trigger an adjustment of the safety factor used in setting
the pacing pulse output energy.

The illustrated device block diagram of Figure 2 is merely exemplary, and
corresponds to the general functional organization of a typical multi-programmable
microprocessor controlled DDD(R) cardiac pacemaker. It is believed that the present
invention is readily practiced in the context of such a device, and that the present invention
can therefore readily be practiced using the basic hardware of existing microprocessor
controlled dual chamber pacemakers, as presently available, with the invention
implemented primarily by means of modifications to the software stored in the ROM 312
of the microcomputer circuit 302. However, the present invention may also be usefully practiced by means of a full custom integrated circuit, for example, a circuit taking the form of a state machine as set forth in the above-cited Betzold et al. patent, in which a state counter serves to control an arithmetic logic unit to perform calculations according to a prescribed sequence of counter controlled steps. As such, the present invention should not be understood to be limited to a cardiac stimulation device having an architecture as illustrated in Figure 2, and a circuit architecture as illustrated in Figure 2 is not believed to be a prerequisite to enjoying the benefits of the present invention.

Furthermore, while a particular dual-chamber implantable cardiac stimulation device and lead system is shown in Figures 1 and 2, the present invention may be usefully practiced in other types of cardiac stimulation devices such as any single, dual or multi-chamber cardiac stimulation device capable of providing cardiac pacing therapies and may further include higher-voltage stimulation therapies for cardioversion and defibrillation. As such, other types of lead systems may be substituted for the particular lead system shown in Figure 1 according to the type of cardiac stimulation device implanted. Unipolar, bipolar, and/or multipolar leads provided with tip, ring, and/or coil electrodes may be used. A lead system may be used to position electrodes within the heart or external to the heart such as epicardial or subcutaneous placements.

In some embodiments of the present invention, an indicator of increased pacing threshold may be related to the occurrence of an arrhythmia. For example, the atrial substrate is believed to be more difficult to capture after an episode of atrial fibrillation or atrial flutter. The time that the increased pacing threshold is expected to remain higher is thought to be related to the duration of the atrial arrhythmia episode. As such, device 26 may include arrhythmia detection capabilities.

The following exemplary arrhythmia detection method corresponds to that employed in commercially marketed Medtronic implantable pacemaker/cardioverter/defibrillators and employs rate/interval based timing criteria as a basic mechanism for detecting the presence of a tachyarrhythmia. To this end, the device defines a set of rate ranges and associated software-defined counters to track the numbers of intervals falling within the defined ranges.

A first rate range may define a minimum R-R or P-P interval used for ventricular fibrillation (VF) or atrial fibrillation detection (AF), respectively, referred to as a
"fibrillation detection interval" or "FDI". An associated VF or AF count preferably indicates how many of a first predetermined number of the preceding intervals were shorter than the FDI. A second rate range may include R-R or P-P intervals shorter than a lower tachycardia detection interval "TDI", and an associated VT count or AT count is incremented in response to an interval shorter than the TDI but longer than the FDI, is not affected by intervals shorter than the FDI, and is reset in response to intervals longer than the TDI. Optionally, the device may include a third rate range including intervals longer than the FDI interval, but shorter than a fast tachycardia interval (FTDI) which is intermediate the lower tachycardia detection interval (TDI) and the lower fibrillation detection interval (FDI).

For purposes of the present example, the interval counts may be used to signal detection of an associated arrhythmia (fibrillation, fast tachycardia or slow tachycardia) when they individually or in combination reach a predetermined value, referred to herein as "number of intervals to detect" or "NID". Each rate zone may have its own defined count and NID, for example "AFNID" for atrial fibrillation detection and "ATNID" for atrial tachycardia detection, or combined counts may be employed. These counts, along with other stored information reflective of the previous series of R-R, P-P, P-R, and R-P intervals such as information regarding the rapidity of onset, the stability of the detected intervals, the duration of continued detection of short intervals, the average interval duration and information derived from analysis of stored EGM segments are used to determine whether tachyarrhythmias are present and to distinguish between different types of tachyarrhythmias.

Other tachyarrhythmia detection methodologies, including detection methods as described in U.S. Pat. No. 5,991,656, issued to Olson, et al., U.S. Pat. No. 5,755,736, issued to Gillberg, et al., both incorporated herein by reference in their entireties, or other known ventricular and/or atrial tachyarrhythmia detection methods may be substituted. It is believed that the automatic safety factor adjustment feature provided by the present invention may be usefully practiced in conjunction with virtually any underlying rate-based arrhythmia detection scheme when arrhythmia detection is selected as an indicator of increased pacing threshold. Other exemplary detection schemes are described in U.S. Pat. No. 4,726,380, issued to Vollmann, U.S. Pat. No. 4,880,005, issued to Pless et al. and
U.S. Pat. No. 4,830,006, issued to Haluska et al., incorporated by reference in their entireties herein.

In selecting indicators of increased pacing threshold, particular types of arrhythmias or arrhythmias that are sustained for a particular duration of time may be selected. When the particular type of arrhythmia or required arrhythmia episode duration is detected, an adjustment of the safety factor used in setting the pulse energy output is triggered, as will be described in greater detail below.

When device 26 shown in Figure 2 is provided with arrhythmia detection capabilities, device 26 may further be equipped with anti-arrhythmia therapy capabilities. Anti-arrhythmia pacing therapies may be delivered by output amplifier circuit 340 under the control of digital controller/timer circuit 330. In accordance with one implementation of the present invention, detection of atrial fibrillation or atrial tachycardia will trigger an increase in the safety factor. Thus, any pacing delivered during and/or for at least a period following an atrial arrhythmia episode will be delivered using a pulse energy set according to the increased safety factor.

As noted previously, the automatically adjusted safety factor feature provided by the present invention may be implemented in a device that further includes high-voltage arrhythmia therapies for cardioversion or defibrillation. An exemplary cardiac pacing/cardioversion/defibrillation/ device in which the present invention may be implemented is disclosed U.S. Pat. No. 5,545,186 issued to Olson et al., incorporated herein by reference in its entirety.

Figure 3 is a flow chart providing an overview of a method for automatically adjusting the safety factor in response to detecting one or more indicators of a likely increase in pacing threshold in accordance with the present invention. Method 400 may be enabled by a clinician to operate continuously such that the safety factor is adjusted when in increased pacing threshold indicator is detected in order to ensure successful capture when and if a pacing therapy is delivered. Thus, method 400 may be operating even when a pacing therapy is not being delivered such that if a pacing therapy becomes necessary the pacing pulse energy delivered will be adequate to capture the heart tissue from the onset of pacing.

At step 405, microcomputer 302 monitors for events that have been previously defined as indicators of a likely increase in pacing threshold. Increased pacing threshold
indicators may be selectable by a clinician and may include, but are not limited to, detection of an arrhythmia, the duration of an arrhythmia episode exceeding a predefined interval, a pacing mode switch, the duration of a pacing mode switch, a refractory sensed event or an event triggered by a refractory sensed event such as a non-competitive atrial pacing period, a lead impedance measurement that is outside a predefined normal lead impedance range, or a change in lead impedance greater than a predefined amount.

If any of the predefined increased threshold indicators are detected by microcomputer 302, as determined at decision step 410, the safety factor is increased to a predetermined maximum value at step 415. An increased safety factor may be applied for increasing the pacing pulse amplitude and/or the pacing pulse width. The maximum safety factor value may be a fixed maximum value, a multiple of the programmed safety factor, the programmed safety factor plus a predetermined increment, or some other function of the programmed safety factor. For example, the programmed safety factor may be set to 1.25 such that the pacing pulse amplitude and/or pulse width is set to 1.25 times the pacing threshold amplitude and/or pulse width. When an increased threshold indicator is detected, the safety factor may be doubled to 2.5 or adjusted to some other setting greater than the programmed value.

It is recognized that in some pacing applications, the pacing pulse energy may be set as the sum of a measured pacing threshold plus a “safety margin” rather than the product of a pacing threshold and a safety factor. It is to be understood that method 400 for increasing a safety factor in response to detecting an increased threshold indicator may equally be used for increasing a “safety margin” or any other parameter used to adjust the pacing output energy to a level that is safely above than a measured threshold in order to ensure capture.

At step 420 an increased safety factor timer may be set. The safety factor may be adjusted to an increased value for a predetermined period of time. The time interval for which the safety factor is increased may depend on the type of increased threshold indicator detected at step 405. For example, if an arrhythmia was detected that lasted several minutes or less, the increased safety factor timer may be set for an interval of only a few minutes. After the increased safety factor timer expires, the safety factor will be reset to its programmed value as will be described below. If an arrhythmia was detected that lasted several hours or even days, e.g., persistent AF or AFL, the increased safety
factor timer may be set for an interval of several hours. In response to other events, such as a large increase in lead impedance, the increased safety factor may be set indefinitely or until clinician intervention. In response to a non-competitive atrial pacing period, the safety factor may be increased to effectively raise the pacing pulse energy for only a single pacing pulse following the NCAP period.

If, at any time after the safety factor has been increased, a pacing threshold search yields a result, as determined at decision step 425, the safety factor may be restored to its programmed value at step 430, and the pacing pulse energy adjusted accordingly. The increased safety factor is intended to ensure an adequate pacing pulse energy when an increased pacing threshold is suspected and a pacing threshold search cannot be performed successfully. Hence, if a valid pacing threshold result is available, the pulse energy may be adjusted appropriately using the programmed safety factor. After restoring the safety factor to the programmed value, method 400 returns to step 405 to monitor again for an increased threshold indicator.

If a pacing threshold search result is not available (decision step 425) at any time during the increased safety factor time interval, method 400 returns to step 405 to continue to monitor for increased threshold indicators. As long as an increased threshold indicator is detected to be present, the safety factor remains at the increased setting.

If an increased threshold indicator is not detected at decision step 410, method 400 proceeds to step 435. If the safety factor is not currently at an increased value, as determined at decision step 435, method 400 returns to step 405 to continue monitoring for increased threshold indicators. If the safety factor is currently greater than the programmed value, i.e., a previous increased threshold indicator detection has triggered an increase in the safety factor, method 400 determines if the safety factor timer has expired at step 440. If the safety factor timer has not expired, method 400 returns to step 405 to continue monitoring for increased threshold indicators.

Once no increased threshold indicators are detected (decision step 410) and the safety factor timer is expired (decision step 440), the safety factor may be adjusted back to the programmed value at step 445. Thus, once conditions that are likely to cause a pacing threshold to be increased are no longer present, and an increased safety factor interval has expired during which time an elevated pacing threshold is expected to have returned to normal, the safety factor may be restored to the programmed value. The safety
factor may be restored to the programmed value at step 445 in a single step adjustment or gradually in stepwise or exponential decrements. Method 400 then returns to step 405 to continue monitoring for increased threshold indicators such that if an indicator is detected during or after the safety factor is adjusted back to a programmed value, the safety factor may again be increased to a maximum value.

Figures 4A through 4C are plots of pulse amplitude changes over time which illustrate changes in the pulse amplitude that may be made in response to automatic adjustments to the safety factor in accordance with the method shown in Figure 3. In Figures 4A through 4C, pacing pulse amplitude is plotted over time. In these examples, the pacing pulse amplitude is shown to be adjusted in response to an automatically adjusted safety factor. However, it is recognized that either or both the pacing pulse amplitude and pacing pulse width may be increased to increase the overall pulse energy according to an increased safety factor or safety margin.

In Figure 4A, a prior pacing threshold search yielded a pacing threshold 502 indicated by a horizontal dashed line. The pacing pulse amplitude is initially set at an amplitude 506 equal to the pacing threshold 502 multiplied by a programmed safety factor value. Pacing pulse amplitude 506 is thus set at a margin 504, safely above the threshold 502.

An increased threshold indicator is detected at time 508 triggering an increase in the safety factor. The pulse amplitude is reset to an increased amplitude 512 equal to the threshold 502 multiplied by the increased safety factor, providing a larger margin 510 above the threshold 502. At the end of an increased safety factor time interval 514, the safety factor is adjusted back to the programmed value. Such adjustment may be made in a stepwise or exponentially decreasing manner as described previously. Thus, the pulse amplitude is decreased at 516 as the safety factor is decreased (shown here in stepwise decrements), back to an amplitude 518 equal to the threshold 502 multiplied by the programmed safety factor value.

In Figure 4B, an initial pacing pulse amplitude 506, set based on a previously measured pacing threshold 502 and a programmed safety factor value, is increased to amplitude 512 after detecting an increased threshold indicator at time 508. However, in the example shown in Figure 4B, a pacing threshold search is performed at 520 yielding a
new pacing threshold 522. The increased safety factor time interval 514 has not yet expired, however, the safety factor is restored to its programmed value upon measuring a pacing threshold successfully. The pacing pulse amplitude is adjusted to a new value 524 equal to the new threshold 522 multiplied by the programmed safety factor value, resulting in a margin 526 above the new threshold 522 corresponding to the programmed safety factor.

In the example shown in Figure 4C, detection of an increased threshold indicator at 508 triggers an increase in the safety factor resulting in an increase in pulse amplitude from amplitude 506 to amplitude 512 as described previously. The safety factor is decreased after the increased safety factor time interval 514 expires, resulting in a decreasing pulse amplitude 516. However, prior to restoration of the programmed safety factor value, a second increased threshold indicator is detected at 530, causing the safety factor to be reset to a high setting and a correspondingly increased pulse amplitude 532. After expiration of a second increased safety factor time interval 536, without any intervening pacing threshold search results or new increased threshold indicator detections, the safety factor is adjusted back to the programmed value, and the pacing pulse amplitude is correspondingly decreased at 538.

Thus, a method for automatically adjusting the safety factor used in setting cardiac pacing pulse energy is provided for use in maintaining capture under conditions normally associated with an increased pacing threshold when an updated pacing threshold measurement may not be available. The detailed descriptions of the methods described herein are intended to illustrate the concept of the present invention. It is recognized that those skilled in the art, having the benefit of the teachings provided herein, may conceive of numerous variations to the methods described herein for automatically adjusting a safety factor or a safety margin in response to various indicators of an increased pacing threshold. The embodiments described herein are intended to be exemplary, therefore, and not limiting with regard to the following claims.
What is claimed is:

1. A method of providing capture management in an implantable medical device, the method comprising:
   monitoring for indicators of a likely increase in pacing threshold; and
   increasing a safety factor used in setting a pacing pulse output energy if an indicator of increased pacing threshold is detected.

2. The method of claim 1 further comprising:
   setting a time interval during which the increased safety factor is maintained; and
   restoring the safety factor to a programmed value after the time interval has expired.

3. The method of claim 2 wherein the duration of the time interval is set according the type of indicator of increased pacing threshold that has been detected.

4. The method of claim 2 further comprising:
   monitoring for indicators of increased threshold during the time interval; and
   resetting the time interval for which the increased safety factor is maintained if a second indicator of increased pacing threshold is detected.

5. The method of claim 1 further comprising:
   performing a pacing threshold search after detecting an indicator of increased pacing threshold; and
   reducing the increased safety factor back to a programmed value if the pacing threshold search yields a result.

6. The method of claim 1, wherein indicators of increased threshold include a change in lead impedance.

7. The method of claim 1, wherein indicators of increased threshold include arrhythmia detections.
8. The method of claim 7, wherein the arrhythmia detections include arrhythmia detections exceeding a predetermined duration.

9. The method of claim 1, wherein indicators of increased threshold include a pacing mode switch.

10. The method of claim 1, wherein indicators of increased threshold include a refractory sensed event or an event triggered by a refractory sensed event.

11. An implantable medical device, comprising:
   a pulse generator for delivering pacing pulses;
   at least one electrode in electrical communication with the pulse generator for delivering the pacing pulses to cardiac tissue; and
   a microprocessor for controlling the pulse generator, receiving sensed data from the at least one electrode, wherein the sensed data includes an indicator of increased pacing threshold, and increasing a safety factor used for setting the pacing pulse energy delivered by the pulse generator when the indicator of increased pacing threshold is detected.
FIG. 3
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61N/37

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 6 061 594 A (ZHOU ET AL) 9 May 2000 (2000-05-09) column 2, line 57 - column 3, line 4 column 6, lines 12-29; figure 3</td>
<td>11</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents:
*A* document defining the general state of the art which is not considered to be of particular relevance
*E* earlier document but published on or after the international filing date
*L* document which may throw doubts on priority claims or which is cited to establish the publication date of another document, or other special reason (as specified)
*O* document referring to an oral discussion, use, exhibition or other means
*P* document published prior to the international filing date but later than the priority date claimed

**T** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Date of the actual completion of the international search

13 April 2005

Date of mailing of the international search report

20/04/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk
Tel: (+31-70) 340-0040, Tx: 3: 551 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Aronsson, F
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>
INTERNATIONAL SEARCH REPORT

Box II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. X Claims Nos.: 1-10
   because they relate to subject matter not required to be searched by this Authority, namely:
   see FURTHER INFORMATION sheet PCT/ISA/210

2. □ Claims Nos.: because they relate to parts of the international Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. □ Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. □ As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.

2. □ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. □ As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. □ No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

□ The additional search fees were accompanied by the applicant's protest.

□ No protest accompanied the payment of additional search fees.
Continuation of Box II.1

Claims Nos.: 1–10

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
Rule 39.1(iv) PCT - Diagnostic method practised on the human or animal body

Claims 1–10 are considered to implicitly refer to therapeutic methods of treatment practised on the human or animal body and diagnostic methods practised on the living human or animal body, due to the provision of results that on their own enable a decision to be made on the treatment necessary (treatment of arrhythmia).

Therapeutic method:
The step of "monitoring for indicators of a likely increase in pacing threshold" includes capture monitoring, which requires the step of delivering a pacing pulse to the heart of a patient, i.e. a therapeutic step.

Diagnostic method:
As indicated by dependent claim 7 and 8 the method may include arrhythmia detection.

According to the PCT neither search (Rule 39.1(iv) PCT) nor examination (Rule 67.1(iv) PCT) is required for such subject-matter.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>EP 1136098 A2</td>
<td>26-09-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2338808 A1</td>
<td>10-02-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2002521156 T</td>
<td>16-07-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0006250 A1</td>
<td>10-02-2000</td>
</tr>
<tr>
<td>US 6456882 B1</td>
<td>24-09-2002</td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td>US 6456879 B1</td>
<td>24-09-2002</td>
<td>US 6615082 B1</td>
<td>02-09-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2003298580 A1</td>
<td>23-04-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2004030748 A2</td>
<td>15-04-2004</td>
</tr>
</tbody>
</table>